Neurology

Officials from the FDA have approved flortaucipir F18 (Tauvid, Eli Lilly) for intravenous injection as the first drug used to help image a distinctive characteristic of Alzheimer disease in the brain called tau pathology.

Despite triptan availability as a migraine-specific rescue, the global burden of migraine morbidity remains high.

The FDA approval of solifenacin succinate marks the first for the treatment of young pediatric patients with NDO.

Officials with the FDA have approved apomorphine hydrochloride sublingual film (APL-130277) for the acute, intermittent treatment of OFF episodes in patients with Parkinson disease.

According to the study authors, patients with MS who underwent the 4-week mindfulness training not only showed greater improvement in processing speed and regulating negative emotions than those who did not participate in any training, but they also improved compared with those who tried adaptive cognitive training (ACT).

These accessible health care professionals are in a pivotal position to guide those who suffer from this neurological disorder to self-treatment or refer more serious cases to physicians.

This new study showed for the first time that an enzyme, known as fatty acid synthase (FASN), specifically may be responsible for causing cognitive deficits.

Individuals with the progressive condition often struggle to control their motor fluctuations.

Purdue University researchers have created technology that uses optical imaging to better help surgeons map out tumors in the body and understand how certain diseases affect activity in the brain.

The study involved measuring the levels and analyzing the expression patterns of more than 3000 proteins in a large number of brain and cerebrospinal fluid samples collected at multiple research centers across the United States.

The kinase inhibitor selumetinib was approved for the treatment of pediatric patients aged 2 years and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.

Eptinezumab-jjmr, the first and only intravenous treatment for migraine prevention, is now commercially available in the United States.

A study by the American Academy of Neurology suggests that taking a low-dose aspirin once per day does not reduce the risk of thinking and memory problems caused by mild cognitive impairment or possible Alzheimer disease.

Ozanimod demonstrated acceptable safety and tolerability in the phase 3 SUNBEAM and RADIANCE part B trials.

The study focused on whether moderate alcohol intake is related to reductions in amyloid-beta deposition or is protective via amyloid-independent mechanisms in the living human brain since little information was available.

The spray is the first nasal spray treatment for seizure cluster rescue.

Few drugs are available to address cognitive decline, but dietary changes, mental and physical activity, and social engagement can all help.

Few drugs are available to address cognitive decline, but dietary changes, mental and physical activity, and social engagement can all help.

Higher dietary intake of flavonols may be associated with a lower risk of developing Alzheimer dementia.

Many options are available, but no single one is effective for all symptoms of this disorder.

The medication works by blocking CGRP receptors, treating a root cause of migraine.

Why is KM taking such a high dose of prednisone?

Study findings provide further basis for dietary interventions as future treatments for disorders such as multiple sclerosis.

The release of generic versions of brand name drugs for patients with multiple sclerosis had little overall effect on the price increase.

The diazepam nasal spray was granted 7 years of Orphan Drug Exclusivity by the FDA Office of Orphan Products Development.